Mitochondrial immune response to SARS-CoV-2 (WP5038)

Homo sapiens

Authors

Gabriel Couillaud , Claire Billingsley , Egon Willighagen , Friederike Ehrhart , Eric Weitz , Finterly Hu , Kingson ''junsheng Thang'' Luc , and Nhung Pham

Activity

Discuss this pathway

Check for ongoing discussions or start your own.

Cited In

• Transcriptional Profiling of SARS-CoV-2-Infected Calu-3 Cells Reveals Immune-Related Signaling Pathways (2024).

Are you planning to include this pathway in your next publication? See How to Cite and add a link here to your paper once it's online.

Organisms

Homo sapiens

Communities

COVID-19

Annotations

Disease Ontology

severe acute respiratory syndrome COVID-19

Pathway Ontology

disease pathway immune response pathway

References

1. The insert sequence in SARS-CoV-2 enhances spike protein cleavage by TMPRSS [Internet]. Meng T, Cao H, Zhang H, Kang Z, Xu D, Gong H, et al. Cold Spring Harbor Laboratory; 2020. Available from: http://dx.doi.org/10.1101/2020.02.08.926006 DOI Scholia
2. SARS coronavirus and innate immunity. Frieman M, Heise M, Baric R. Virus Res. 2008 Apr;133(1):101–12. PubMed Europe PMC Scholia
3. An N-terminal addressing sequence targets NLRX1 to the mitochondrial matrix. Arnoult D, Soares F, Tattoli I, Castanier C, Philpott DJ, Girardin SE. J Cell Sci. 2009 Sep 1;122(Pt 17):3161–8. PubMed Europe PMC Scholia
4. Crosstalk of reactive oxygen species and NF-κB signaling. Morgan MJ, Liu Z gang. Cell Res. 2011 Jan;21(1):103–15. PubMed Europe PMC Scholia
5. Mitochondria in innate immune responses. West AP, Shadel GS, Ghosh S. Nat Rev Immunol. 2011 Jun;11(6):389–402. PubMed Europe PMC Scholia
6. NLRX1 protein attenuates inflammatory responses to infection by interfering with the RIG-I-MAVS and TRAF6-NF-κB signaling pathways. Allen IC, Moore CB, Schneider M, Lei Y, Davis BK, Scull MA, et al. Immunity. 2011 Jun 24;34(6):854–65. PubMed Europe PMC Scholia
7. The NLR protein, NLRX1, and its partner, TUFM, reduce type I interferon, and enhance autophagy. Lei Y, Wen H, Ting JPY. Autophagy. 2013 Mar;9(3):432–3. PubMed Europe PMC Scholia
8. NLRX1 Mediates MAVS Degradation To Attenuate the Hepatitis C Virus-Induced Innate Immune Response through PCBP2. Qin Y, Xue B, Liu C, Wang X, Tian R, Xie Q, et al. J Virol. 2017 Nov 14;91(23):e01264-17. PubMed Europe PMC Scholia
9. Mitochondrial electron transport chain, ROS generation and uncoupling (Review). Zhao RZ, Jiang S, Zhang L, Yu ZB. Int J Mol Med. 2019 Jul;44(1):3–15. PubMed Europe PMC Scholia
10. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Gordon DE, Jang GM, Bouhaddou M, Xu J, Obernier K, White KM, et al. Nature. 2020 Jul;583(7816):459–68. PubMed Europe PMC Scholia
11. The mechanistic overview of SARS-CoV-2 using angiotensin-converting enzyme 2 to enter the cell for replication: possible treatment options related to the renin-angiotensin system. Offringa A, Montijn R, Singh S, Paul M, Pinto YM, Pinto-Sietsma SJ. Eur Heart J Cardiovasc Pharmacother. 2020 Sep 1;6(5):317–25. PubMed Europe PMC Scholia
12. Kawasaki-like diseases and thrombotic coagulopathy in COVID-19: delayed over-activation of the STING pathway? Berthelot JM, Drouet L, Lioté F. Emerg Microbes Infect. 2020 Dec;9(1):1514–22. PubMed Europe PMC Scholia
13. Comparative multiplexed interactomics of SARS-CoV-2 and homologous coronavirus non-structural proteins identifies unique and shared host-cell dependencies. Davies JP, Almasy KM, McDonald EF, Plate L. bioRxiv. 2020 Jul 14;2020.07.13.201517. PubMed Europe PMC Scholia
14. Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity. Shin D, Mukherjee R, Grewe D, Bojkova D, Baek K, Bhattacharya A, et al. Nature. 2020 Nov;587(7835):657–62. PubMed Europe PMC Scholia
15. SARS-CoV-2 Orf9b suppresses type I interferon responses by targeting TOM70. Jiang HW, Zhang HN, Meng QF, Xie J, Li Y, Chen H, et al. Cell Mol Immunol. 2020 Sep;17(9):998–1000. PubMed Europe PMC Scholia
16. Genes encoding ACE2, TMPRSS2 and related proteins mediating SARS-CoV-2 viral entry are upregulated with age in human cardiomyocytes. Robinson EL, Alkass K, Bergmann O, Maguire JJ, Roderick HL, Davenport AP. J Mol Cell Cardiol. 2020 Oct;147:88–91. PubMed Europe PMC Scholia
17. SARS-CoV-2 ORF9c Is a Membrane-Associated Protein that Suppresses Antiviral Responses in Cells. Dominguez Andres A, Feng Y, Campos AR, Yin J, Yang CC, James B, et al. bioRxiv. 2020 Aug 19;2020.08.18.256776. PubMed Europe PMC Scholia
18. Evasion of Type I Interferon by SARS-CoV-2. Xia H, Cao Z, Xie X, Zhang X, Chen JYC, Wang H, et al. Cell Rep. 2020 Oct 6;33(1):108234. PubMed Europe PMC Scholia
19. SARS-CoV-2 induces double-stranded RNA-mediated innate immune responses in respiratory epithelial derived cells and cardiomyocytes. Li Y, Renner DM, Comar CE, Whelan JN, Reyes HM, Cardenas-Diaz FL, et al. bioRxiv. 2020 Nov 2;2020.09.24.312553. PubMed Europe PMC Scholia
20. Mitochondria: In the Cross Fire of SARS-CoV-2 and Immunity. Burtscher J, Cappellano G, Omori A, Koshiba T, Millet GP. iScience. 2020 Oct 23;23(10):101631. PubMed Europe PMC Scholia
21. The Mitochondrial Outer Membrane Protein Tom70-Mediator in Protein Traffic, Membrane Contact Sites and Innate Immunity. Kreimendahl S, Rassow J. Int J Mol Sci. 2020 Oct 1;21(19):7262. PubMed Europe PMC Scholia
22. Role of Oxidative Stress on SARS-CoV (SARS) and SARS-CoV-2 (COVID-19) Infection: A Review. Suhail S, Zajac J, Fossum C, Lowater H, McCracken C, Severson N, et al. Protein J. 2020 Dec;39(6):644–56. PubMed Europe PMC Scholia
23. Coronavirus biology and replication: implications for SARS-CoV-2. V’kovski P, Kratzel A, Steiner S, Stalder H, Thiel V. Nat Rev Microbiol. 2021 Mar;19(3):155–70. PubMed Europe PMC Scholia
24. Experimental and natural evidence of SARS-CoV-2-infection-induced activation of type I interferon responses. Banerjee A, El-Sayes N, Budylowski P, Jacob RA, Richard D, Maan H, et al. iScience. 2021 May 21;24(5):102477. PubMed Europe PMC Scholia